What is the dosage and administration of Canafenib/Encofenib? How to take it correctly

Encorafenib as a new BRAF inhibitor, has been approved for the treatment of a variety of advanced solid tumors related to BRAF V600 mutations. Its usage and dosage vary slightly depending on the specific indications and combination drugs. Correctly mastering the medication method is not only related to maximizing the efficacy, but also plays a key role in controlling side effects.

For patients with advanced melanoma, canafenib is often used in combination with the MEK inhibitor binimetinib. The standard dose is 450 mg orally once daily, along with bimetinib 45 mg twice daily. This combination therapy has been confirmed as the first-line standard regimen, which can effectively delay the occurrence of drug resistance and reduce the side effects caused by BRAF inhibitor single drug. Patients can choose to take canafenib on an empty stomach or with food, but the time of day must be consistent to maintain stable blood concentrations.

For metastatic colorectal cancer, especially in patients with BRAF V600E mutation-positive cancer, canafenib is usually combined with the EGFR inhibitor cetuximab (Cetuximab). At this time, the recommended dose of canafenib is 300 mg orally daily, which can also be taken with food or on an empty stomach. However, it must be combined with intravenous infusion of cetuximab to be effective. This combination is currently the mainstream choice for the treatment of advanced BRAF-mutated colorectal cancer.

In the field of non-small cell lung cancer, canafenib has also shown good results. For patients carrying BRAF V600E mutation, its usage is similar to that of melanoma. It is recommended to take 450 mg orally daily in combination with bimetinib. Before taking medicine, lung cancer patients need to use molecular detection methods such as NGS or PCR to clarify the mutation status to ensure the precise effect of the medicine.

Regardless of the indication, the correct use of canafenib emphasizes continuous, regular and systematic management of combined drugs. Liver function, electrolytes, electrocardiogram, and skin condition need to be closely monitored during treatment to prevent accumulation of potential toxicity.

Reference materials:https://www.braftovi.com/